Voyager Therapeutics advances tau-silencing gene therapy program
I'm LongbridgeAI, I can summarize articles.Voyager Therapeutics presented favorable toxicology data for its tau-silencing gene therapy VY1706, showing CNS delivery and up to 75% tau reduction in primates. The company plans a clinical trial in H2 2026 following FDA IND clearance. While analysts rate the stock a Buy with a $25 target, TipRanks' AI suggests Neutral due to weak financials and bearish technical signals despite positive catalysts.
Voyager Therapeutics ( (VYGR) ) has provided an update.
On July 13, 2026, Voyager Therapeutics presented three- and six-month good laboratory practice toxicology data for its investigational tau-silencing gene therapy VY1706 at the Alzheimer’s Association International Conference, showing a favorable tolerability profile in non-human primates with no adverse findings in the central nervous system, dorsal root ganglia, or peripheral organs at doses up to 5 x 10^13 vector genomes per kilogram. The data also showed that a single intravenous dose achieved broad, durable, dose-dependent central nervous system delivery with up to 75% reduction of tau mRNA and protein in key Alzheimer’s-relevant brain regions over six months, and identified the ALPL receptor as a mediator of blood-brain barrier transport, supporting cross-species translatability and underpinning the company’s plan to start a multi-site, open-label, dose-escalation clinical trial of VY1706 in the second half of 2026 after U.S. FDA investigational new drug clearance in June 2026.
The most recent analyst rating on (VYGR) stock is a Buy
with a $25.00 price target.
To see the full list of analyst forecasts on Voyager Therapeutics stock,
see the VYGR Stock Forecast page.
Spark’s Take on VYGR Stock
According to Spark, TipRanks’ AI Analyst, VYGR is a Neutral.
The score is held down primarily by weak financial performance (sharp losses and heavy cash burn) and bearish technical signals (price below major moving averages with negative MACD). Positive corporate catalysts (IND clearance and added financing flexibility) provide some support but do not outweigh current profitability and cash-flow risks.
To see Spark’s full report on VYGR stock,
click here.
More about Voyager Therapeutics
Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies, including investigational tau-silencing treatments, for neurodegenerative diseases such as Alzheimer’s disease. Its programs target disease-driving proteins in the central nervous system, aiming to modify underlying biology rather than only treating symptoms.
Average Trading Volume: 595,963
Technical Sentiment Signal: Strong Sell
Current Market Cap: $207.8M